Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

Approximately 8% to 19% of patients with acute myeloid leukemia (AML) have isocitrate dehydrogenase-2 (IDH2) mutations, which occur at active site arginine residues R140 and R172. IDH2 mutations produce an oncometabolite, 2-hydroxyglutarate (2-HG), which leads to DNA and histone hypermethylation and...

Descripció completa

Dades bibliogràfiques
Autors principals:	Stein, EM, Dinardo, CD, Fathi, AT, Pollyea, DA, Stone, RM, Altman, JK, Roboz, GJ, Patel, MR, Collins, R, Flinn, IW, Sekeres, MA, Stein, AS, Kantarjian, HM, Levine, RL, Vyas, P, Macbeth, KJ, Tosolini, A, Vanoostendorp, J, Xu, Q, Gupta, I, Lila, T, Risueno, A, Yen, KE, Wu, B, Attar, EC, Tallman, MS, De Botton, S
Format:	Journal article
Idioma:	English
Publicat:	American Society of Hematology 2018

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

Ítems similars